Tela Bio Inc (TELA)

$5.98

-0.14

(-2.29%)▲

Market is closed - opens 7 PM, 23 May 2024

Insights on Tela Bio Inc

  • Decreasing Revenue

    Revenue is down for the last 2 quarters, 16.99M → 16.60M (in $), with an average decrease of 2.3% per quarter

  • Increasing Net Profit

    Netprofit is up for the last 2 quarters, -12.89M → -5.66M (in $), with an average increase of 127.7% per quarter

  • Vs BSX

    In the last 1 year, Boston Scientific Corp. has given 41.0% return, outperforming this stock by 77.3%

  • Vs BSX

    In the last 3 years, Boston Scientific Corp. has given 79.7% return, outperforming this stock by 133.5%

Performance

  • $5.72
    $6.26
    $5.98
    downward going graph

    4.27%

    Downside

    Day's Volatility :8.55%

    Upside

    4.47%

    downward going graph
  • $4.23
    $11.26
    $5.98
    downward going graph

    29.26%

    Downside

    52 Weeks Volatility :62.43%

    Upside

    46.89%

    downward going graph

Returns

PeriodTela Bio IncIndex (Russel 2000)
3 Months
-13.31%
0.0%
6 Months
26.19%
0.0%
1 Year
-36.32%
0.0%
3 Years
-54.05%
-20.1%

Highlights

Market Capitalization
154.8M
Book Value
$0.58
Earnings Per Share (EPS)
-1.64
Wall Street Target Price
14.2
Profit Margin
-63.82%
Operating Margin TTM
-74.72%
Return On Assets TTM
-43.28%
Return On Equity TTM
-459.89%
Revenue TTM
63.1M
Revenue Per Share TTM
2.61
Quarterly Revenue Growth YOY
39.4%
Gross Profit TTM
27.8M
EBITDA
-44.4M
Diluted Eps TTM
-1.64
Quarterly Earnings Growth YOY
0.0
EPS Estimate Current Year
-1.52
EPS Estimate Next Year
-1.22
EPS Estimate Current Quarter
-0.5
EPS Estimate Next Quarter
-0.45

Analyst Recommendation

Buy
    90%Buy
    9%Hold
    0
    0%Sell
Based on 11 Wall street analysts offering stock ratings for Tela Bio Inc(by analysts ranked 0 to 5 stars)
Based on 11 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
10
10
10
Hold
1
1
1
Sell
00
00
00

Analyst Forecast

What analysts predicted

Upside of 137.46%

Current $5.98
Target $14.20

Company Financials

FY18Y/Y Change
Revenue
8.3M
↑ 94.91%
Net Income
-21.1M
↓ 1.13%
Net Profit Margin
-254.92%
↑ 247.65%
FY19Y/Y Change
Revenue
15.4M
↑ 86.68%
Net Income
-25.8M
↑ 22.34%
Net Profit Margin
-167.05%
↑ 87.87%
FY20Y/Y Change
Revenue
18.2M
↑ 17.91%
Net Income
-31.9M
↑ 23.54%
Net Profit Margin
-175.03%
↓ 7.98%
FY21Y/Y Change
Revenue
29.5M
↑ 61.77%
Net Income
-36.1M
↑ 13.28%
Net Profit Margin
-122.56%
↑ 52.47%
FY22Y/Y Change
Revenue
41.4M
↑ 40.58%
Net Income
-44.3M
↑ 22.78%
Net Profit Margin
-107.05%
↑ 15.51%
FY23Y/Y Change
Revenue
58.5M
↑ 41.13%
Net Income
-46.7M
↑ 5.25%
Net Profit Margin
-79.83%
↑ 27.22%
Q4 FY22Q/Q Change
Revenue
11.6M
↑ 4.15%
Net Income
-9.8M
↓ 18.16%
Net Profit Margin
-84.08%
↑ 22.93%
Q1 FY23Q/Q Change
Revenue
11.9M
↑ 2.47%
Net Income
-14.0M
↑ 43.74%
Net Profit Margin
-117.94%
↓ 33.86%
Q2 FY23Q/Q Change
Revenue
14.5M
↑ 21.71%
Net Income
-10.8M
↓ 23.18%
Net Profit Margin
-74.44%
↑ 43.5%
Q3 FY23Q/Q Change
Revenue
15.1M
↑ 3.85%
Net Income
-11.0M
↑ 1.55%
Net Profit Margin
-72.79%
↑ 1.65%
Q4 FY23Q/Q Change
Revenue
17.0M
↑ 12.93%
Net Income
-12.9M
↑ 17.64%
Net Profit Margin
-75.83%
↓ 3.04%
Q1 FY24Q/Q Change
Revenue
16.6M
↓ 2.32%
Net Income
-5.7M
↓ 56.08%
Net Profit Margin
-34.1%
↑ 41.73%
FY18Y/Y Change
Total Assets
27.2M
↑ 75.3%
Total Liabilities
165.1M
↑ 33.45%
FY19Y/Y Change
Total Assets
67.9M
↑ 149.47%
Total Liabilities
37.0M
↓ 77.61%
FY20Y/Y Change
Total Assets
86.5M
↑ 27.29%
Total Liabilities
37.4M
↑ 1.28%
FY21Y/Y Change
Total Assets
62.5M
↓ 27.66%
Total Liabilities
42.4M
↑ 13.39%
FY22Y/Y Change
Total Assets
67.9M
↑ 8.49%
Total Liabilities
53.6M
↑ 26.16%
FY23Y/Y Change
Total Assets
78.0M
↑ 15.02%
Total Liabilities
59.2M
↑ 10.49%
Q4 FY22Q/Q Change
Total Assets
67.9M
↓ 14.72%
Total Liabilities
53.6M
↓ 4.82%
Q1 FY23Q/Q Change
Total Assets
58.8M
↓ 13.36%
Total Liabilities
55.6M
↑ 3.92%
Q2 FY23Q/Q Change
Total Assets
94.4M
↑ 60.55%
Total Liabilities
54.4M
↓ 2.28%
Q3 FY23Q/Q Change
Total Assets
87.3M
↓ 7.49%
Total Liabilities
56.8M
↑ 4.38%
Q4 FY23Q/Q Change
Total Assets
78.0M
↓ 10.62%
Total Liabilities
59.2M
↑ 4.23%
Q1 FY24Q/Q Change
Total Assets
71.8M
↓ 7.96%
Total Liabilities
57.5M
↓ 2.9%
FY18Y/Y Change
Operating Cash Flow
-19.9M
↑ 21.73%
Investing Cash Flow
-1.6M
↑ 1442.57%
Financing Cash Flow
27.4M
↑ 4.1%
FY19Y/Y Change
Operating Cash Flow
-25.5M
↑ 28.1%
Investing Cash Flow
-12.0M
↑ 669.0%
Financing Cash Flow
65.5M
↑ 139.05%
FY20Y/Y Change
Operating Cash Flow
-24.5M
↓ 4.18%
Investing Cash Flow
9.1M
↓ 176.14%
Financing Cash Flow
44.4M
↓ 32.23%
FY21Y/Y Change
Operating Cash Flow
-30.4M
↑ 24.44%
Investing Cash Flow
-627.0K
↓ 106.87%
Financing Cash Flow
585.0K
↓ 98.68%
FY22Y/Y Change
Operating Cash Flow
-40.7M
↑ 33.9%
Investing Cash Flow
-1.9M
↑ 198.56%
Financing Cash Flow
40.9M
↑ 6883.25%
Q4 FY22Q/Q Change
Operating Cash Flow
-11.0M
↑ 43.59%
Investing Cash Flow
-1.0M
↑ 260.69%
Financing Cash Flow
-219.0K
↓ 100.63%
Q1 FY23Q/Q Change
Operating Cash Flow
-11.6M
↑ 5.38%
Investing Cash Flow
-115.0K
↓ 89.01%
Financing Cash Flow
-235.0K
↑ 7.31%
Q2 FY23Q/Q Change
Operating Cash Flow
-11.3M
↓ 2.68%
Investing Cash Flow
-157.0K
↑ 36.52%
Financing Cash Flow
46.4M
↓ 19848.51%

Technicals Summary

Sell

Neutral

Buy

Tela Bio Inc is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.

More on Technical Analysis

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Tela Bio Inc
Tela Bio Inc
33.92%
26.19%
-36.32%
-54.05%
-54.16%
Stryker Corporation
Stryker Corporation
0.86%
12.4%
15.49%
28.53%
77.74%
Boston Scientific Corp.
Boston Scientific Corp.
11.25%
36.51%
40.96%
76.8%
100.56%
Edwards Lifesciences Corp.
Edwards Lifesciences Corp.
3.89%
34.72%
1.32%
-5.35%
56.97%
Abbott Laboratories
Abbott Laboratories
-3.84%
0.25%
-4.89%
-12.22%
35.01%
Medtronic Plc
Medtronic Plc
5.71%
8.68%
-4.84%
-33.51%
-4.04%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Tela Bio Inc
Tela Bio Inc
NA
NA
NA
-1.52
-4.6
-0.43
NA
0.58
Stryker Corporation
Stryker Corporation
37.6
37.6
2.92
11.96
0.19
0.07
0.01
50.33
Boston Scientific Corp.
Boston Scientific Corp.
63.33
63.33
1.8
2.33
0.09
0.05
NA
13.56
Edwards Lifesciences Corp.
Edwards Lifesciences Corp.
38.77
38.77
5.19
2.76
0.21
0.12
NA
11.82
Abbott Laboratories
Abbott Laboratories
32.15
32.15
5.99
4.63
0.15
0.06
0.02
22.31
Medtronic Plc
Medtronic Plc
26.83
26.83
1.52
5.2
0.08
0.04
0.03
38.95
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Tela Bio Inc
Tela Bio Inc
Buy
$154.8M
-54.16%
NA
-63.82%
Stryker Corporation
Stryker Corporation
Buy
$125.6B
77.74%
37.6
16.03%
Boston Scientific Corp.
Boston Scientific Corp.
Buy
$110.8B
100.56%
63.33
12.05%
Edwards Lifesciences Corp.
Edwards Lifesciences Corp.
Buy
$54.4B
56.97%
38.77
23.01%
Abbott Laboratories
Abbott Laboratories
Buy
$179.5B
35.01%
32.15
13.96%
Medtronic Plc
Medtronic Plc
Buy
$112.2B
-4.04%
26.83
13.0%

Institutional Holdings

  • Essex Woodlands Health Ventures

    16.68%

  • Orbimed Advisors, LLC

    11.50%

  • First Light Asset Management, LLC

    10.36%

  • Nantahala Capital Management, LLC

    8.91%

  • AIGH Capital Management, LLC

    5.59%

  • BlackRock Inc

    4.37%

Company Information

tela bio, inc., a surgical reconstruction company, was created out of the desire to do things differently. combining the drive and innovation of a start-up with a seasoned medical technology team, the company aims to commercialize a portfolio of products that are purposefully designed to address a range of unmet needs in soft tissue repair. based in malvern, pennsylvania, this science-driven company is collaborating with leading surgeons to reinvigorate the soft tissue reconstruction market and bring cost-effective solutions to hospitals, surgeons and patients. please see our social media community guidelines at http://bit.ly/1uvcx0l

Organization
Tela Bio Inc
Employees
227
CEO
Mr. Antony Koblish
Industry
Health Technology

Discover More

FAQs